the cliff
Patent cliff
Drugs ranked by the soonest barrier to generic / biosimilar entry. Each row shows the earliest-expiring patent OR FDA exclusivity for that drug — whichever falls first determines when competitive pressure begins.
- May 26, 20303.6ypatentQamzovameloxicamNanjing Delova Biotech Co Ltd
- May 26, 20303.6ypatentVenclextavenetoclax$ABBVAbbVie Inc.
- May 28, 20303.6ypatentSymbicort Aerosphere(budesonide + formoterol fumarate)AstraZeneca Pharmaceuticals LP
- May 28, 20303.6ypatentBevespi Aerosphere(formoterol fumarate + glycopyrrolate)AstraZeneca Pharmaceuticals LP
- May 28, 20303.6yNCETryptyracoltremon$ALCALCON INC
- Jun 2, 20303.6ypatentStivargaregorafenibBayer AG
- Jun 7, 20303.6ypatentParlodelbromocriptine mesylateValidus Pharmaceuticals LLC
- Jun 11, 20303.6yNCEIbtrozitaletrectinib adipate$NUVBNuvation Bio Inc.
- Jun 16, 20303.6ypatentSumatriptansumatriptan [INN]Florida Pharmaceutical Products LLC
- Jun 17, 20303.6ypatentSimbrinza(brimonidine tartrate + brinzolamide)$NVSNOVARTIS AG
- Jun 21, 20303.6ypatentIdhifaenasidenib mesylateBristol-Myers Squibb Co
- Jun 24, 20303.6ypatentAristadaaripiprazole lauroxilAlkermes US Holdings Inc
- Jul 2, 20303.7yNCEZegfrovysunvozertinibDizal Pharmaceutical Co Ltd
- Jul 3, 20303.7yNCEEkterlysebetralstat [INN]$KALVKalVista Pharmaceuticals, Inc.
- Jul 13, 20303.7ypatentSegluromet(ertugliflozin + metformin hydrochloride)$MRKMerck & Co., Inc.
- Jul 13, 20303.7ypatentERTUGLIFLOZINERTUGLIFLOZIN$MRKMerck & Co., Inc.
- Jul 21, 20303.7ypatentAuryxiaferric citrate$AKBAAkebia Therapeutics, Inc.
- Jul 23, 20303.7yNCEAnzupgodelgocitinibLeo Pharma AS
- Jul 28, 20303.7ypatentXospatagilteritinib fumarateAstellas Pharma US Inc
- Jul 28, 20303.7yNCESephiencesepiapterin$PTCPTC INC.
- Jul 29, 20303.7ypatentParsabivetelcalcetide hydrochloride$AMGNAMGEN INC
- Jul 31, 20303.7yNCEVizzaceclidine$LENZLENZ Therapeutics, Inc.
- Aug 2, 20303.8ypatentAllegrafexofenadine hydrochlorideChattem Inc
- Aug 6, 20303.8yNCEModeysodordaviprone hydrochloride$JAZZJazz Pharmaceuticals plc
- Aug 12, 20303.8yNCEBrinsupribrensocatib$INSMINSMED Inc
- Aug 14, 20303.8yODE-438Melblezmelphalan hydrochloride$DCTHDELCATH SYSTEMS, INC.
- Aug 28, 20303.8ypatentBrexafemmeibrexafungerp citrate$GSKGSK plc
- Aug 29, 20303.8yNCEWayrilzrilzabrutinib$SNYSanofi
- Aug 31, 20303.8ypatentBETAMETHASONE DIPROPIONATEBETAMETHASONE DIPROPIONATEPerrigo New York Inc
- Sep 1, 20303.8ypatentLUMISIGHTPEGULICIANINELUMICELL
- Sep 21, 20303.9ypatentCeftaroline Fosamilceftaroline fosamilApotex Corp
- Sep 22, 20303.9ypatentGLYCEROL PHENYLBUTYRATEGLYCEROL PHENYLBUTYRATELupin Ltd
- Sep 25, 20303.9yNCEInluriyoimlunestrant tosylateEli Lilly and Co
- Sep 25, 20303.9yNCEPalsonifypaltusotine hydrochloride$CRNXCrinetics Pharmaceuticals, Inc.
- Sep 30, 20303.9yNCERhapsidoremibrutinib$NVSNOVARTIS AG
- Oct 1, 20303.9ypatentAmzeeqminocycline$DERMJourney Medical Corp
- Oct 24, 20304.0yNCELynkuetelinzanetantBayer USA LLC
- Oct 27, 20304.0ypatentJevtanacabazitaxelSanofi-Aventis US LLC
- Nov 3, 20304.0yNCEKygevvi(doxecitine + doxribtimine)UCB SA
- Nov 13, 20304.0yNCEKomziftiziftomenib$KURAKura Oncology, Inc.
- Nov 18, 20304.1ypatentAkynzeo(fosnetupitant chloride hydrochloride + palonosetron hydrochloride)Helsinn Therapeutics (US) Inc
- Nov 19, 20304.1yNCEHyrnuosevabertinibBayer AG
- Nov 24, 20304.1ypatentEliglustat Tartrateeliglustat tartrateAizant Drug Research Solutions Pvt Ltd
- Dec 1, 20304.1ypatentLanthanum Carbonatelanthanum carbonateBarr Laboratories Inc
- Dec 6, 20304.1ypatentRenvelasevelamer carbonateSanofi-Aventis US LLC
- Dec 14, 20304.1ypatentAXPAXLIaxitinib$OCULOCULAR THERAPEUTIX, INC
- Dec 19, 20304.1yNCEMyqorzoaficamten$CYTKCYTOKINETICS INC
- Dec 30, 20304.2yNCENereustradipitant$VNDAVanda Pharmaceuticals Inc.
- Jan 12, 20314.2yNCEZycubocopper histidinateSentynl Therapeutics Inc
- Jan 14, 20314.2ypatentPliaglis(lidocaine + tetracaine)Taro Pharmaceutical USA Inc
sourced from FDA Orange Book · approved drugs only · biologics + biosimilars excluded (those live in the Purple Book — coming soon)